Commercial dynamics for cell therapies are shifting: Gilead reported an 11% drop in cell‑therapy revenue for the quarter, citing lower demand for Yescarta and Tecartus, while a separate clinical study found axicabtagene ciloleucel (axi‑cel) outperformed conventional first‑line therapy in high‑risk large B‑cell lymphoma. The juxtaposition highlights market and access pressures facing commercial CAR‑T franchises even as clinical data suggest expanding therapeutic roles for CAR‑T products in earlier lines of care.